AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21173411 — intervention group
Group type: EXPERIMENTAL
Intervention: Unblinded echinacea pills
Number of subjects: 719
Study 21173411 — intervention group
Group type: COMPARATOR
Intervention: Blinded placebo pills
Number of subjects: 719
Study 21173411 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label echinacea pills
Number of subjects: 719
Study 18000268 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D
Number of subjects: 0
Study 18000268 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid, Calcium, Vitamin D
Number of subjects: 0
Study 18000268 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Fibre
Number of subjects: 0
Study 18000268 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Meat
Number of subjects: 0
Study 18000268 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Folate Levels and High Alcohol Consumption
Number of subjects: 0
Study 18000268 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin and Mineral Supplements
Number of subjects: 0
Study 15030841 — intervention group
Group type: EXPERIMENTAL
Intervention: Empty-bag technique (EBT) using Healon5
Number of subjects: 40
Study 15030841 — intervention group
Group type: COMPARATOR
Intervention: Standard injection method using Healon5
Number of subjects: 40
Study 15030841 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 40
Study 11211574 — intervention group
Group type: EXPERIMENTAL
Intervention: Chyawanprash (15 g/d)
Number of subjects: 10
Study 11211574 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C (500 mg/d)
Number of subjects: 10
Study 9580349 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoendoscopic inspection alone
Number of subjects: 167
Study 9580349 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital dye staining (1% methylene blue)
Number of subjects: 167
Study 9580349 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosaic pattern
Number of subjects: 167
Study 9580349 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalloped folds
Number of subjects: 167
Study 9580349 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in the number or loss of duodenal folds
Number of subjects: 167
Study 7920493 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal occult blood screening
Number of subjects: 451
Study 7920493 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic presentation
Number of subjects: 451
Study 7920493 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall quality of life coefficient for surviving patients
Number of subjects: 451
Study 2894739 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.3 mg intrathecally
Number of subjects: 40
Study 2894739 — intervention group
Group type: COMPARATOR
Intervention: Saline intrathecally
Number of subjects: 40
Study 31785463 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin for 6 cycles (arm A)
Number of subjects: 120
Study 31785463 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral trofosfamide (arm B)
Number of subjects: 120
Study 31785463 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (arm A)
Number of subjects: 120
Study 29742699 — intervention group
Group type: EXPERIMENTAL
Intervention: Active photobiomodulation in the sublingual region
Number of subjects: 0
Study 29742699 — intervention group
Group type: EXPERIMENTAL
Intervention: Active photobiomodulation along the spinal cord
Number of subjects: 0
Study 29742699 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with photobiomodulation on the skin in the region of the radial artery
Number of subjects: 0
Study 29742699 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation on the skin in the region of the radial artery
Number of subjects: 0
Study 29742699 — intervention group
Group type: COMPARATOR
Intervention: Sham photobiomodulation in the sublingual region
Number of subjects: 0
Study 29742699 — intervention group
Group type: COMPARATOR
Intervention: Sham photobiomodulation along the spinal cord
Number of subjects: 0
Study 28421782 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF)
Number of subjects: 144
Study 28421782 — intervention group
Group type: COMPARATOR
Intervention: Milk substitutes (MS)
Number of subjects: 144
Study 28421782 — intervention group
Group type: COMPARATOR
Intervention: Control (no analgesic maneuver)
Number of subjects: 144
Study 25911608 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (VR) protocols
Number of subjects: 220
Study 24330893 — intervention group
Group type: EXPERIMENTAL
Intervention: Withania somnifera extract (WSE) 500 mg/d
Number of subjects: 60
Study 24330893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21478328 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (a selective vitamin D receptor activator)
Number of subjects: 0
Study 21478328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18646364 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue Covarine
Number of subjects: 0
Study 18646364 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste formulations containing Blue Covarine
Number of subjects: 0
Study 18646364 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 0
Study 15111229 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective priming using unrelated prime-target pairs in a naming task with a short stimulus onset asynchrony (250 ms).
Number of subjects: 0
Study 10417584 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CO2/Er:YAG laser treatment
Number of subjects: 20
Study 10417584 — intervention group
Group type: COMPARATOR
Intervention: CO2 laser alone
Number of subjects: 20
Study 10417584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 20
Study 7589376 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized L-ASA (90 mg.ml-1)
Number of subjects: 9
Study 7589376 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo (glycine solution, 30 mg.ml-1)
Number of subjects: 9
Study 2239115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high frequency ventilation (IHFV) at 160 b.p.m.
Number of subjects: 10
Study 2239115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high frequency ventilation (IHFV) at 60 b.p.m.
Number of subjects: 10
Study 2239115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high frequency ventilation (IHFV) with constant Paco2
Number of subjects: 10
Study 2239115 — intervention group
Group type: COMPARATOR
Intervention: Normal ventilation and high frequency ventilation (HFV)
Number of subjects: 10
Study 7365058 — intervention group
Group type: EXPERIMENTAL
Intervention: Family self-control instruction (experimental group)
Number of subjects: 33
Study 7365058 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 33
Study 7365058 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments (2, 6, and 12 months)
Number of subjects: 33
Study 31125276 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 95
Study 31125276 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 95
Study 29065020 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Feedback (PF) video
Number of subjects: 21
Study 29065020 — intervention group
Group type: COMPARATOR
Intervention: Scheduled repeated practice (21 trainees)
Number of subjects: 21
Study 26920359 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR <60 mL/min/1.73 m(2) and UACR ≥30 mg/g
Number of subjects: 665
Study 26920359 — intervention group
Group type: EXPERIMENTAL
Intervention: UACR ≥30 mg/g
Number of subjects: 665
Study 26920359 — intervention group
Group type: COMPARATOR
Intervention: Neither marker of CKD (eGFR ≥60 mL/min/1.73 m(2) and UACR <30 mg/g)
Number of subjects: 665
Study 25935942 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 200
Study 25935942 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin non-users
Number of subjects: 200
Study 21700602 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 μg once daily
Number of subjects: 36
Study 21700602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19318523 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing intervention program
Number of subjects: 80
Study 19318523 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 17626026 — intervention group
Group type: COMPARATOR
Intervention: One AEC
Number of subjects: 60
Study 17626026 — intervention group
Group type: EXPERIMENTAL
Intervention: Two AECs
Number of subjects: 60
Study 14734673 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐TRODAT‐1 SPECT imaging in MSA-P
Number of subjects: 49
Study 14734673 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐TRODAT‐1 SPECT imaging in MSA-C
Number of subjects: 49
Study 14734673 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐TRODAT‐1 SPECT imaging in PD
Number of subjects: 49
Study 14734673 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐TRODAT‐1 SPECT imaging in MSA-P and MSA-C
Number of subjects: 49
Study 14734673 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc‐TRODAT‐1 SPECT imaging in MSA-P and PD
Number of subjects: 49
Study 11124917 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Triggered Ventilation (PTV)
Number of subjects: 142
Study 11124917 — intervention group
Group type: COMPARATOR
Intervention: Conventional Ventilation (CMV)
Number of subjects: 142
Study 9671427 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol hydrochloride 0.50% (Betoptic) administered to 15 POAG and 7 NTG eyes
Number of subjects: 48
Study 9671427 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol hydrochloride 0.25% (Betoptic S) administered to 17 POAG and 9 NTG eyes
Number of subjects: 48
Study 8024354 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutropin (0.2 mg/kg/day)
Number of subjects: 46
Study 8024354 — intervention group
Group type: EXPERIMENTAL
Intervention: Protropin (0.2 mg/kg/day)
Number of subjects: 46
Study 8024354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 2925041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous phenylalanine before treatment with carbidopa
Number of subjects: 12
Study 2925041 — intervention group
Group type: COMPARATOR
Intervention: Carbidopa treatment
Number of subjects: 12
Study 31722694 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured lifestyle education programme (STEPWISE)
Number of subjects: 51
Study 29759616 — intervention group
Group type: EXPERIMENTAL
Intervention: CFAE ablation
Number of subjects: 66
Study 29759616 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA ablation
Number of subjects: 66
Study 29759616 — intervention group
Group type: EXPERIMENTAL
Intervention: CFAE or CEA ablation
Number of subjects: 66
Study 25968599 — intervention group
Group type: COMPARATOR
Intervention: Multi-component intervention programme targeting school and family environment, including healthy diet and physical activity promotion, activities to increase physical activity, participation in the 'Villa Vitality' programme, healthy cooking skills workshops, and provision of information to families.
Number of subjects: 1000
Study 25968599 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group).
Number of subjects: 1000
Study 25968599 — intervention group
Group type: COMPARATOR
Intervention: Multi-component intervention programme targeting school and family environment.
Number of subjects: 1000
Study 24035099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.2 mg, orally, Study 1)
Number of subjects: 32
Study 24035099 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (22 mg, intravenously, Study 2)
Number of subjects: 32
Study 24035099 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group for both studies)
Number of subjects: 32
Study 21900646 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop dynamic cardiac baroreflex sensitivity (sequence technique)
Number of subjects: 10
Study 21900646 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop low-frequency baroreflex transfer function gain
Number of subjects: 10
Study 21900646 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-loop low-frequency transfer function gain (white-noise stimulation)
Number of subjects: 10
Study 21900646 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal gain of carotid-cardiac baroreflex stimulus-response curve
Number of subjects: 10
Study 19443532 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 19443532 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 0
Study 17680911 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab + SIT-grass
Number of subjects: 92
Study 17680911 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab + SIT-birch
Number of subjects: 92
Study 17680911 — intervention group
Group type: COMPARATOR
Intervention: placebo + SIT-grass
Number of subjects: 92
Study 17680911 — intervention group
Group type: COMPARATOR
Intervention: placebo + SIT-birch
Number of subjects: 92
Study 17680911 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year after treatment (all groups)
Number of subjects: 92
Study 14981776 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus RNA
Number of subjects: 161
Study 14981776 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterovirus RNA
Number of subjects: 161
Study 14981776 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic control children
Number of subjects: 161
Study 14981776 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-positive children
Number of subjects: 161
Study 14981776 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall persistence of viral RNA
Number of subjects: 161
Study 11752106 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg subcutaneous methylnaltrexone plus morphine
Number of subjects: 12
Study 11752106 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg subcutaneous methylnaltrexone plus morphine
Number of subjects: 12
Study 11752106 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.05 mg/kg intravenously)
Number of subjects: 12
Study 9695655 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-L-fucosidase (ALF) activity in patients with recurrent cholelithiasis
Number of subjects: 36
Study 9695655 — intervention group
Group type: EXPERIMENTAL
Intervention: AST activity in patients with recurrent cholelithiasis
Number of subjects: 36
Study 9695655 — intervention group
Group type: EXPERIMENTAL
Intervention: AST activity in patients with ductal and/or bladder cholelithiasis
Number of subjects: 36
Study 9695655 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT activity in patients with recurrent cholelithiasis
Number of subjects: 36
Study 9695655 — intervention group
Group type: EXPERIMENTAL
Intervention: ALT activity in patients with ductal and/or bladder cholelithiasis
Number of subjects: 36
Study 9695655 — intervention group
Group type: EXPERIMENTAL
Intervention: GGT activity in patients with recurrent cholelithiasis
Number of subjects: 36
Study 9695655 — intervention group
Group type: EXPERIMENTAL
Intervention: GGT activity in patients with ductal and/or bladder cholelithiasis
Number of subjects: 36
Study 9695655 — intervention group
Group type: EXPERIMENTAL
Intervention: GGT activity in patients with focal changes in the liver
Number of subjects: 36
Study 8033514 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (240 kJ/h)
Number of subjects: 21
Study 8033514 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 21
Study 2558404 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 10
Study 2558404 — intervention group
Group type: COMPARATOR
Intervention: Non-fractioned heparin (NFH)
Number of subjects: 10
Study 4142795 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin 150 mg followed by radiation
Number of subjects: 20
Study 4142795 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 20
Study 31375279 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy at 66.6Gy
Number of subjects: 250
Study 31375279 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy alone (observation group)
Number of subjects: 250
Study 28302407 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H7N1 vaccine (3.75μg or 7.5μg hemagglutinin with AS03A or AS03B)
Number of subjects: 360
Study 28302407 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H7N1 vaccine
Number of subjects: 360
Study 28302407 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 360
Study 26180217 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a free, proactive quitline
Number of subjects: 112
Study 23075913 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogen clamp
Number of subjects: 640
Study 23075913 — intervention group
Group type: COMPARATOR
Intervention: Gomco
Number of subjects: 640
Study 23075913 — intervention group
Group type: COMPARATOR
Intervention: Plastibell
Number of subjects: 640
Study 21562746 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg ZnSO(4) daily
Number of subjects: 36
Study 21562746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18457756 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention for pre- and interconceptional women
Number of subjects: 692
Study 17084137 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) delivered by general practitioners (GPs)
Number of subjects: 0
Study 17084137 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 14717683 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical practice guideline (CPG) provided to the intervention group after pre-test assessment.
Number of subjects: 0
Study 14717683 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CPG provided).
Number of subjects: 0
Study 11335734 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg at 0 and 4 or 0 and 6 months
Number of subjects: 1026
Study 11335734 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg at 0 and 6 or 0, 2, and 4 or 0, 1, and 6 months
Number of subjects: 1026
Study 11335734 — intervention group
Group type: EXPERIMENTAL
Intervention: One 10-microg dose
Number of subjects: 1026
Study 11335734 — intervention group
Group type: EXPERIMENTAL
Intervention: One 5-microg dose
Number of subjects: 1026
Study 11335734 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or three 5-microg doses
Number of subjects: 1026
Study 11335734 — intervention group
Group type: COMPARATOR
Intervention: 2-dose regimen of Recombivax HB
Number of subjects: 1026
Study 11335734 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 10-microg doses
Number of subjects: 1026
Study 9453874 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive laparoscopic tubal ligation under sedation and local anesthesia
Number of subjects: 14
Study 9453874 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic tubal ligation under general anesthesia
Number of subjects: 14
Study 8392285 — intervention group
Group type: EXPERIMENTAL
Intervention: AZQ at 15 mg/day for 3 days i.v. every 4 weeks
Number of subjects: 249
Study 8392285 — intervention group
Group type: COMPARATOR
Intervention: BCNU at 200 mg i.v. every 8 weeks
Number of subjects: 249
Study 3521859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetropium bromide (50 mg BID)
Number of subjects: 40
Study 3521859 — intervention group
Group type: COMPARATOR
Intervention: Octylonium bromide (20 mg TID)
Number of subjects: 40
Study 29610401 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent recombinant influenza vaccine (RIV4)
Number of subjects: 219
Study 29610401 — intervention group
Group type: COMPARATOR
Intervention: Inactivated influenza vaccine
Number of subjects: 219
Study 27834742 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia plus antishivering treatment
Number of subjects: 120
Study 27834742 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 120
Study 27834742 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 120
Study 24105103 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300/12.5 mg
Number of subjects: 30
Study 24105103 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 300/25 mg
Number of subjects: 30
Study 24105103 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 300/12.5 mg
Number of subjects: 30
Study 24105103 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 300/25 mg
Number of subjects: 30
Study 22664783 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg once-daily
Number of subjects: 1280
Study 22664783 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted according to Japanese guidelines)
Number of subjects: 1280
Study 20832925 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg caffeine
Number of subjects: 36
Study 20832925 — intervention group
Group type: COMPARATOR
Intervention: 100 mg caffeine
Number of subjects: 36
Study 20832925 — intervention group
Group type: COMPARATOR
Intervention: 200 mg caffeine
Number of subjects: 36
Study 20832925 — intervention group
Group type: COMPARATOR
Intervention: 0 mg caffeine
Number of subjects: 36
Study 18395480 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (0.012 mg/kg/day)
Number of subjects: 57
Study 18395480 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dosing (ID) GH regimen
Number of subjects: 57
Study 18395480 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dosing (FD) GH regimen (0.012 mg/kg/day)
Number of subjects: 57
Study 18395480 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dosing (FD) GH regimen
Number of subjects: 57
Study 18395480 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 57
Study 15737659 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 146
Study 15737659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 14649535 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education before cardiac catheterization
Number of subjects: 62